title: Clinical and immunogenetic characteristics of fulminant type 1 diabetes associated with pregnancy.
abstract: OBJECTIVE
  The objective of this study was to characterize the clinical and immunogenetic features of Japanese pregnancy-associated fulminant type 1 diabetes (PF). A group of patients with PF was compared with a group of patients of child-bearing age with fulminant type 1 diabetes that was not associated with pregnancy (NPF) in a nationwide survey conducted from 2000-2004.
  
  
  METHODS
  The clinical characteristics of the 22 patients in the PF group were compared with those of the 48 patients in the NPF group. Human leukocyte antigen (HLA) class II DR and DQ genotyping of 17 PF and 20 NPF patients was performed.
  
  
  RESULTS
  Arterial pH was significantly lower (P = 0.0366), and amylase values tended to increase in PF patients compared with NPF patients (P = 0.0515). In 22 PF patients, 18 developed disease during pregnancy (26.3 wk; range, 7-38), whereas four cases occurred immediately after delivery (10.5 d; range, 7-14 d). Twelve cases that developed during pregnancy resulted in stillbirth (67%), and five of the six fetal cases that survived were delivered by cesarean section. The haplotype frequency of HLA DRB1*0901-DQB1*0303 in PF was significantly higher than those in NPF (P = 0.0244) and controls (P = 0.0001), whereas that of DRB1*0405-DQB1*0401 in NPF was significantly higher than those in PF (P = 0.0162) and controls (P < 0.0001).
  
  
  CONCLUSIONS
  The clinical symptoms of PF patients were more severe than those of NPF patients, and the prognosis of their fetuses was extremely poor. The type 1 diabetes-susceptible HLA class II haplotype is distinct in PF and NPF patients, suggesting that different HLA haplotypes underlie the presentation of PF or NPF.
authors.affiliation: Department of Internal Medicine, Ehime Prefectural Imabari Hospital, Imabari 794-0006, Japan.
authors.forename: I
authors.initials: I
authors.lastname: Shimizu
authors.forename: H
authors.initials: H
authors.lastname: Makino
authors.forename: A
authors.initials: A
authors.lastname: Imagawa
authors.forename: H
authors.initials: H
authors.lastname: Iwahashi
authors.forename: Y
authors.initials: Y
authors.lastname: Uchigata
authors.forename: A
authors.initials: A
authors.lastname: Kanatsuka
authors.forename: E
authors.initials: E
authors.lastname: Kawasaki
authors.forename: T
authors.initials: T
authors.lastname: Kobayashi
authors.forename: A
authors.initials: A
authors.lastname: Shimada
authors.forename: T
authors.initials: T
authors.lastname: Maruyama
authors.forename: T
authors.initials: T
authors.lastname: Hanafusa
mesh_terms: D000293:Adolescent; D000328:Adult; D001323:Autoantibodies / Q000276:immunology; D003922:Diabetes Mellitus, Type 1 / Q000235:genetics* / Q000276:immunology* / Q000473:pathology; D005260:Female; D005313:Fetal Death; D005838:Genotype; D006683:HLA-DQ Antigens / Q000235:genetics / Q000276:immunology; D006684:HLA-DR Antigens / Q000235:genetics / Q000276:immunology; D006239:Haplotypes; D006801:Humans; D008875:Middle Aged; D011247:Pregnancy; D011254:Pregnancy in Diabetics / Q000235:genetics* / Q000276:immunology* / Q000473:pathology
chemical_list: D001323:Autoantibodies; D006683:HLA-DQ Antigens; D006684:HLA-DR Antigens